Adicet Bio NASDAQ: ACET reported positive clinical data for prula-cel, its investigational allogenei

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises t

Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephr

Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's r

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and ra

-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR--

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnolo

Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss nar

Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing al

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnolo

HC Wainwright & Co. analyst Robert Burns reiterates Adicet Bio (NASDAQ:ACET) with a Buy and m

The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in A

Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing a

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing al

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate ca

Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their se

Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseas

The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical

Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the pric

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.99) per share which beat the analyst conse

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnolo

SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compa

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(1.88) per share which beat the analyst conse

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and lo

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the pric

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(2.94) per share which beat the analyst conse

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and ra

Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing al

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim

Shares of Adicet Bio are trading lower after the clinical stage biotechnology company announced a on

HC Wainwright & Co. analyst Robert Burns maintains Adicet Bio (NASDAQ:ACET) with a Buy and ra

Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and raises the pric

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephri

Clinical data to date supports a potentially transformational approach to treating autoimmune diseas

Guggenheim analyst Yatin Suneja reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $7 p

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.34) per share which missed the analyst con

HC Wainwright & Co. analyst Robert Burns assumes Adicet Bio (NASDAQ:ACET) with a Buy rating a